PTPN11 and myeloid leukemia: In addition, one third of patients with juvenile myelomonocytic leukemia without the syndrome harbor somatic mutations of Ptpn11, which were predicted to cause a gain of function in SHP2 that was proposed to act as an oncoprotein in these myeloid leukemias[54].